Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

ImmunityBio (IBRX) Return on Assets (2016 - 2025)

ImmunityBio (IBRX) has disclosed Return on Assets for 11 consecutive years, with 0.76% as the latest value for Q3 2025.

  • On a quarterly basis, Return on Assets rose 70.0% to 0.76% in Q3 2025 year-over-year; TTM through Sep 2025 was 0.76%, a 70.0% increase, with the full-year FY2024 number at 0.93%, up 41.0% from a year prior.
  • Return on Assets was 0.76% for Q3 2025 at ImmunityBio, up from 1.04% in the prior quarter.
  • In the past five years, Return on Assets ranged from a high of 0.76% in Q3 2025 to a low of 1.49% in Q2 2023.
  • A 5-year average of 1.22% and a median of 1.22% in 2023 define the central range for Return on Assets.
  • Peak YoY movement for Return on Assets: tumbled -33bps in 2021, then skyrocketed 70bps in 2025.
  • ImmunityBio's Return on Assets stood at 1.34% in 2021, then rose by 13bps to 1.17% in 2022, then decreased by -7bps to 1.25% in 2023, then rose by 11bps to 1.11% in 2024, then surged by 32bps to 0.76% in 2025.
  • Per Business Quant, the three most recent readings for IBRX's Return on Assets are 0.76% (Q3 2025), 1.04% (Q2 2025), and 1.19% (Q1 2025).